PMH is a 220-bed, internationally recognized pediatric facility that treats children and adolescents from around the state with approximately 250,000 patient visits (inpatient and outpatient) each year.
In addition to providing hospital-based care, the Child and Adolescent Health Service is committed to population health and ambulatory care programs aimed at providing services for children and adolescents to promote life-long health. This includes preventing health problems through promoting wellbeing, early detection of diseases and intervention and provision of services in the community rather than a hospital setting.
The Paediatric Haematology/Oncology Total Care Unit (Ward 3B) at Princess Margaret Hospital is the sole tertiary referral centre in Western Australia for the diagnostic and therapeutic management of children diagnosed with all forms of malignant and non-malignant haematological disorders. In addition, the total care unit has an active haemopoietic stem cell transplant facility. Adolescents comprise 20-25% of the unit’s caseload but only approximately half of the expected cases diagnosed yearly in WA are referred.
Medulloblastoma research – 3D Molecular Imaging Technology
Brain tumours are the second most common cancer affecting children. In contrast to children with leukaemia who have an excellent chance of a cure, those diagnosed with the most common form of childhood brain tumour, medulloblastoma, have a substantially greater risk of succumbing to their disease. Of particular concern is the less than 50 per cent survival rate for children with high-risk medulloblastoma. On top of this, children with brain tumours face the possibility of brain damage and disability associated with surgery, radiotherapy and chemotherapy.
Further study and research is required to better understand the development and behaviour of medulloblastoma. This requires the application of 3D Molecular Imaging Technology; technology that is currently not available in the Southern Hemisphere. Ultimately, it is hoped that this work will lead to better and more effective treatment options for our young medulloblastoma patients and a more optimistic future for children affected by this life threatening disease.
To learn more about the machine the Project will purchase follow the link here >>>> IVIS Quantum FX
PMH | Ward 3B | Research
Princess Margaret Hospital (PMH)
PMH is a 220-bed, internationally recognized pediatric facility that treats children and adolescents from around the state with approximately 250,000 patient visits (inpatient and outpatient) each year.
In addition to providing hospital-based care, the Child and Adolescent Health Service is committed to population health and ambulatory care programs aimed at providing services for children and adolescents to promote life-long health. This includes preventing health problems through promoting wellbeing, early detection of diseases and intervention and provision of services in the community rather than a hospital setting.
For more information see http://www.pmh.health.wa.gov.au/brochures/consumers/cahs0105.pdf
Ward 3B
The Paediatric Haematology/Oncology Total Care Unit (Ward 3B) at Princess Margaret Hospital is the sole tertiary referral centre in Western Australia for the diagnostic and therapeutic management of children diagnosed with all forms of malignant and non-malignant haematological disorders. In addition, the total care unit has an active haemopoietic stem cell transplant facility. Adolescents comprise 20-25% of the unit’s caseload but only approximately half of the expected cases diagnosed yearly in WA are referred.
For more information see http://www.ihea.org.au/technical_resources/journal/Autum%202007Dransfield.pdf
Medulloblastoma research – 3D Molecular Imaging Technology
Brain tumours are the second most common cancer affecting children. In contrast to children with leukaemia who have an excellent chance of a cure, those diagnosed with the most common form of childhood brain tumour, medulloblastoma, have a substantially greater risk of succumbing to their disease. Of particular concern is the less than 50 per cent survival rate for children with high-risk medulloblastoma. On top of this, children with brain tumours face the possibility of brain damage and disability associated with surgery, radiotherapy and chemotherapy.
Further study and research is required to better understand the development and behaviour of medulloblastoma. This requires the application of 3D Molecular Imaging Technology; technology that is currently not available in the Southern Hemisphere. Ultimately, it is hoped that this work will lead to better and more effective treatment options for our young medulloblastoma patients and a more optimistic future for children affected by this life threatening disease.
To learn more about the machine the Project will purchase follow the link here >>>> IVIS Quantum FX
For more information please contact Princess Margaret Hospital on (08) 9340 8222 or via the web at http://www.pmh.health.wa.gov.au/forms/compliments.php